Download PDF
Semin Respir Crit Care Med 2013; 34(04): 448-458
DOI: 10.1055/s-0033-1351118
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Pharmacological Therapies for Prevention and Early Treatment of Acute Lung Injury

Enrique Ortiz-Diaz
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
,
Emir Festic
2   Division of Pulmonary Medicine, Department of Critical Care Medicine, Mayo Clinic, Jacksonville, Florida
,
Ognjen Gajic
1   Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota
,
Joseph E. Levitt
3   Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, California
› Author Affiliations
Further Information

Publication History

Publication Date:
11 August 2013 (online)

    Permissions and Reprints

Abstract

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40%. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.

Keywords

acute lung injury - acute respiratory distress syndrome - multiorgan dysfunction syndrome - lung injury prediction score
 

  • References

  • 1 Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest 2007; 131 (2) 554-562
    CrossrefPubMedGoogle Scholar
  • 2 Phua J, Badia JR, Adhikari NK , et al. Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Respir Crit Care Med 2009; 179 (3) 220-227
    CrossrefPubMedGoogle Scholar
  • 3 Li G, Malinchoc M, Cartin-Ceba R , et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med 2011; 183 (1) 59-66
    CrossrefPubMedGoogle Scholar
  • 4 Wilcox ME, Herridge MS. Long-term outcomes in patients surviving acute respiratory distress syndrome. Semin Respir Crit Care Med 2010; 31 (1) 55-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experemental approaches. Drugs 2010; 70 (10) 1255-1282
    CrossrefPubMedGoogle Scholar
  • 6 Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006; 21 (3) 119-143
    CrossrefPubMedGoogle Scholar
  • 7 Levitt JE, Bedi H, Calfee CS, Gould MK, Matthay MA. Identification of early acute lung injury at initial evaluation in an acute care setting prior to the onset of respiratory failure. Chest 2009; 135 (4) 936-943
    CrossrefPubMedGoogle Scholar
  • 8 Gajic O, Dabbagh O, Park PK , et al; on behalf of the U.S. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG–LIPS). Early identification of patients at risk of acute lung injury evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 2011; 183: 462-470
    CrossrefPubMedGoogle Scholar
  • 9 The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342 (18) 1301-1308
    CrossrefPubMedGoogle Scholar
  • 10 Eder AF, Herron Jr RM, Strupp A , et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50 (8) 1732-1742
    CrossrefPubMedGoogle Scholar
  • 11 Gajic O, Dara SI, Mendez JL , et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004; 32 (9) 1817-1824
    CrossrefPubMedGoogle Scholar
  • 12 Iscimen R, Cartin-Ceba R, Yilmaz M , et al. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 2008; 36 (5) 1518-1522
    CrossrefPubMedGoogle Scholar
  • 13 Yilmaz M, Keegan MT, Iscimen R , et al. Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med 2007; 35 (7) 1660-1666 , quiz 1667
    CrossrefPubMedGoogle Scholar
  • 14 Hou PCJ, Elie-Turenne M , et al. A survey on behalf of USCIITG-LIPS Investigators: towards standardization of a Checklist for Lung Injury Prevention (CLIP). Crit Care Med 2010; ; Supplement a576
    PubMedGoogle Scholar
  • 15 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2, Suppl): S26-S34
    CrossrefPubMedGoogle Scholar
  • 16 Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31 (4, Suppl): S329-S336
    CrossrefPubMedGoogle Scholar
  • 17 Asaduzzaman M, Lavasani S, Rahman M , et al. Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 2009; 37 (4) 1389-1396
    CrossrefPubMedGoogle Scholar
  • 18 Yiming MT, Lederer DJ, Sun L, Huertas A, Issekutz AC, Bhattacharya S. Platelets enhance endothelial adhesiveness in high tidal volume ventilation. Am J Respir Cell Mol Biol 2008; 39 (5) 569-575
    CrossrefPubMedGoogle Scholar
  • 19 Zarbock A, Ley K. The role of platelets in acute lung injury (ALI). Front Biosci 2009; 14: 150-158
    PubMedGoogle Scholar
  • 20 Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2009; 40 (2) 123-134
    CrossrefPubMedGoogle Scholar
  • 21 Lösche W, Boettel J, Kabisch B, Winning J, Claus RA, Bauer M. Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?. Thrombosis 2012; 2012: 720254
    PubMedGoogle Scholar
  • 22 Song C, Suzuki S, Kubo H , et al. Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats. Thorax 2004; 59 (1) 39-44
    CrossrefPubMedGoogle Scholar
  • 23 Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009; 119 (11) 3450-3461
    PubMedGoogle Scholar
  • 24 Chelucci GL, Boncinelli S, Marsili M , et al. Aspirin effect on early and late changes in acute lung injury in sheep. Intensive Care Med 1993; 19 (1) 13-21
    CrossrefPubMedGoogle Scholar
  • 25 Erlich JM, Talmor DS, Cartin-Ceba R, Gajic O, Kor DJ. Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 2011; 139 (2) 289-295
    CrossrefPubMedGoogle Scholar
  • 26 O'Neal Jr HR, Koyama T, Koehler EA , et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39 (6) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 27 Kor DJ, Erlich J, Gong MN , et al; U.S. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39 (11) 2393-2400
    CrossrefPubMedGoogle Scholar
  • 28 Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208
    PubMedGoogle Scholar
  • 29 Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122 (6) 743-752
    CrossrefPubMedGoogle Scholar
  • 30 Suter PM. Nebulised heparin: a new approach to the treatment of acute lung injury?. Crit Care 2008; 12 (4) 170
    CrossrefPubMedGoogle Scholar
  • 31 Enkhbaatar P, Cox RA, Traber LD , et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med 2007; 35 (12) 2805-2810
    CrossrefPubMedGoogle Scholar
  • 32 Enkhbaatar P, Esechie A, Wang J , et al. Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. Clin Sci (Lond) 2008; 114 (4) 321-329
    CrossrefPubMedGoogle Scholar
  • 33 Murakami K, McGuire R, Cox RA , et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002; 18 (3) 236-241
    CrossrefPubMedGoogle Scholar
  • 34 Cox Jr CS, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993; 176 (4) 339-349
    PubMedGoogle Scholar
  • 35 Tasaki O, Mozingo DW, Dubick MA, Goodwin CW, Yantis LD, Pruitt Jr BA. Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model. Crit Care Med 2002; 30 (3) 637-643
    CrossrefPubMedGoogle Scholar
  • 36 Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009; 30 (2) 249-256
    CrossrefPubMedGoogle Scholar
  • 37 Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil 1998; 19 (3) 210-212
    CrossrefPubMedGoogle Scholar
  • 38 Holt J, Saffle JR, Morris SE, Cochran A. Use of inhaled heparin/N-acetylcystine in inhalation injury: does it help?. J Burn Care Res 2008; 29 (1) 192-195
    PubMedGoogle Scholar
  • 39 Thompson BT. Corticosteroids for ARDS. Minerva Anestesiol 2010; 76 (6) 441-447
    PubMedGoogle Scholar
  • 40 Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol 2006; 533 (1-3) 2-14
    CrossrefPubMedGoogle Scholar
  • 41 Marik PE, Meduri GU, Rocco PR, Annane D. Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011; 27 (3) 589-607
    CrossrefPubMedGoogle Scholar
  • 42 Abe M, Goya T, Mitsuyama T, Torisu M, Furukawa T. Evaluation of the effects of steroids on experimental septic lung injury. Prostaglandins Leukot Essent Fatty Acids 1996; 54 (2) 123-128
    CrossrefPubMedGoogle Scholar
  • 43 Chen CM, Wang LF, Su B, Hsu HH. Methylprednisolone effects on oxygenation and histology in a rat model of acute lung injury. Pulm Pharmacol Ther 2003; 16 (4) 215-220
    CrossrefPubMedGoogle Scholar
  • 44 Kuwabara K, Furue S, Tomita Y , et al. Effect of methylprednisolone on phospholipase A(2) activity and lung surfactant degradation in acute lung injury in rabbits. Eur J Pharmacol 2001; 433 (2-3) 209-216
    CrossrefPubMedGoogle Scholar
  • 45 Shiue ST, Thrall RS. Effect of corticosteroid therapy on the acute injury and recovery stage of oleic acid induced lung injury in the rat. Exp Lung Res 1991; 17 (3) 629-638
    CrossrefPubMedGoogle Scholar
  • 46 Modig J, Borg T. High-dose methylprednisolone in a porcine model of ARDS induced by endotoxemia. Acta Chir Scand Suppl 1985; 526: 94-103
    PubMedGoogle Scholar
  • 47 Butler Jr RR, Spicer KM. Indomethacin and dexamethasone decrease oleic acid-induced pulmonary protein leak in rabbits. Circ Shock 1986; 20 (3) 217-229
    PubMedGoogle Scholar
  • 48 Cheney Jr FW, Huang TH, Gronka R. Effects of methylprednisolone on experimental pulmonary injury. Ann Surg 1979; 190 (2) 236-242
    CrossrefPubMedGoogle Scholar
  • 49 Jansen NJ, van Oeveren W, Hoiting BH, Wildevuur CR. Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits. Inflammation 1991; 15 (2) 91-101
    CrossrefPubMedGoogle Scholar
  • 50 Gates S, Huang T, Cheney FW. Effects of methylprednisolone on resolution of acid-aspiration pneumonitis. Arch Surg 1983; 118 (11) 1262-1265
    CrossrefPubMedGoogle Scholar
  • 51 Hamelberg W, Bosomworth PP. Aspiration pneumonitis: experimental studies and clinical observations. Anesth Analg 1964; 43: 669-677
    PubMedGoogle Scholar
  • 52 Bone RC, Fisher Jr CJ, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987; 92 (6) 1032-1036
    CrossrefPubMedGoogle Scholar
  • 53 Weigelt JA, Norcross JF, Borman KR, Snyder III WH. Early steroid therapy for respiratory failure. Arch Surg 1985; 120 (5) 536-540
    CrossrefPubMedGoogle Scholar
  • 54 Bernard GR, Luce JM, Sprung CL , et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317 (25) 1565-1570
    CrossrefPubMedGoogle Scholar
  • 55 Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138 (1) 62-68
    CrossrefPubMedGoogle Scholar
  • 56 Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336 (7651) 1006-1009
    CrossrefPubMedGoogle Scholar
  • 57 Lee HS, Lee JM, Kim MS, Kim HY, Hwangbo B, Zo JI. Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome. Ann Thorac Surg 2005; 79 (2) 405-410
    CrossrefPubMedGoogle Scholar
  • 58 Annane D, Sébille V, Bellissant E. Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34 (1) 22-30
    CrossrefPubMedGoogle Scholar
  • 59 Confalonieri M, Urbino R, Potena A , et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171 (3) 242-248
    CrossrefPubMedGoogle Scholar
  • 60 Forsgren PE, Modig JA, Dahlbäck CM, Axelsson BI. Prophylactic treatment with an aerosolized corticosteroid liposome in a porcine model of early ARDS induced by endotoxaemia. Acta Chir Scand 1990; 156 (6-7) 423-431
    PubMedGoogle Scholar
  • 61 Walther S, Jansson I, Berg S, Lennquist S. Pulmonary granulocyte accumulation is reduced by nebulized corticosteroid in septic pigs. Acta Anaesthesiol Scand 1992; 36 (7) 651-655
    CrossrefPubMedGoogle Scholar
  • 62 Walther S, Jansson I, Berg S, Olsson Rex L, Lennquist S. Corticosteroid by aerosol in septic pigs—effects on pulmonary function and oxygen transport. Intensive Care Med 1993; 19 (3) 155-160
    CrossrefPubMedGoogle Scholar
  • 63 Wang J, Zhang L, Walther SM. Inhaled budesonide in experimental chlorine gas lung injury: influence of time interval between injury and treatment. Intensive Care Med 2002; 28 (3) 352-357
    CrossrefPubMedGoogle Scholar
  • 64 Jansson A-H, Eriksson C, Wang X. Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats. Vascul Pharmacol 2005; 43 (2) 101-111
    CrossrefPubMedGoogle Scholar
  • 65 Smith A, Brown R, Jugg B , et al. The effect of steroid treatment with inhaled budesonide or intravenous methylprednisolone on phosgene-induced acute lung injury in a porcine model. Mil Med 2009; 174 (12) 1287-1294
    PubMedGoogle Scholar
  • 66 Ortiz-Diaz E, Li G, Kor D , et al. Preadmission use of inhaled corticosteroids is associated with a reduced risk of direct acute lung injury/acute respiratory distress syndrome. Chest 2011; 140: 912A
    CrossrefPubMedGoogle Scholar
  • 67 Karnatovskaia LV, Lee AS, Gajic O, Festic E. The influence of prehospital systemic corticosteroid use on development of acute respiratory distress syndrome and hospital outcomes. Crit Care Med 2013; May 8 (e-pub ahead of print). DOI: 10.1097/CCM.0b013e31828a1fc7.
    PubMedGoogle Scholar
  • 68 Berthiaume Y, Matthay MA. Alveolar edema fluid clearance and acute lung injury. Respir Physiol Neurobiol 2007; 159 (3) 350-359
    CrossrefPubMedGoogle Scholar
  • 69 Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82 (3) 569-600
    PubMedGoogle Scholar
  • 70 McAuley DF, Frank JA, Fang X, Matthay MA. Clinically relevant concentrations of beta2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit Care Med 2004; 32 (7) 1470-1476
    CrossrefPubMedGoogle Scholar
  • 71 Khimenko PL, Barnard JW, Moore TM, Wilson PS, Ballard ST, Taylor AE. Vascular permeability and epithelial transport effects on lung edema formation in ischemia and reperfusion. J Appl Physiol 1994; 77 (3) 1116-1121
    PubMedGoogle Scholar
  • 72 Khimenko PL, Barnard JW, Moore TM, Wilson PS, Ballard ST, Taylor AE. Vascular permeability and epithelial transport effects on lung edema formation in ischemia and reperfusion. J Appl Physiol 1994; 77 (3) 1116-1121
    PubMedGoogle Scholar
  • 73 Frank AJ, Thompson BT. Pharmacological treatments for acute respiratory distress syndrome. Curr Opin Crit Care 2010; 16 (1) 62-68
    CrossrefPubMedGoogle Scholar
  • 74 Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome. Crit Care 2004; 8 (1) 25-32
    CrossrefPubMedGoogle Scholar
  • 75 Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173 (3) 281-287
    CrossrefPubMedGoogle Scholar
  • 76 Sartori C, Allemann Y, Duplain H , et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346 (21) 1631-1636
    CrossrefPubMedGoogle Scholar
  • 77 Matthay MA, Brower RG, Carson S , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184 (5) 561-568
    CrossrefPubMedGoogle Scholar
  • 78 Gao Smith F, Perkins GD, Gates S , et al; BALTI-2 study investigators. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379 (9812) 229-235
    CrossrefPubMedGoogle Scholar
  • 79 Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007; 7 (5) 358-368
    CrossrefPubMedGoogle Scholar
  • 80 Kouroumichakis I, Papanas N, Proikaki S, Zarogoulidis P, Maltezos E. Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011; 22 (2) 125-133
    CrossrefPubMedGoogle Scholar
  • 81 Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009; 15 (4) 325-334
    CrossrefPubMedGoogle Scholar
  • 82 Bajwa EK, Malhotra CK, Thompson BT, Christiani DC, Gong MN. Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study. Crit Care Med 2012; 40 (5) 1470-1477
    CrossrefPubMedGoogle Scholar
  • 83 Craig TR, Duffy MJ, Shyamsundar M , et al. A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011; 183 (5) 620-626
    CrossrefPubMedGoogle Scholar
  • 84 Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med 2009; 37 (8) 2455-2464
    CrossrefPubMedGoogle Scholar
  • 85 Imai Y, Kuba K, Penninger JM. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 2007; 64 (15) 2006-2012
    CrossrefPubMedGoogle Scholar
  • 86 Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006; 6 (3) 271-276
    CrossrefPubMedGoogle Scholar
  • 87 Yao S, Feng D, Wu Q, Li K, Wang L. Losartan attenuates ventilator-induced lung injury. J Surg Res 2008; 145 (1) 25-32
    CrossrefPubMedGoogle Scholar
  • 88 Bechara RI, Pelaez A, Palacio A , et al. Angiotensin II mediates glutathione depletion, transforming growth factor-beta1 expression, and epithelial barrier dysfunction in the alcoholic rat lung. Am J Physiol Lung Cell Mol Physiol 2005; 289 (3) L363-L370
    CrossrefPubMedGoogle Scholar
  • 89 Gong MN, Bajwa EK, Thompson BT, Christiani DC. Use of ACE inhibitors and development and outcome in ARDS. Am J Respir Crit Care Med 2009; 179: A5095
    PubMedGoogle Scholar
  • 90 Trillo-Alvarez CA, Kashyap R, Kojicic M , et al. Chronic use of angiotensin pathway inhibitors is associated with a decreased risk of acute respiratory distress syndrome [abstract]. Am J Respir Crit Care Med 2009; 179: A4638
    PubMedGoogle Scholar
  • 91 Watkins TR, Lemos-Filho L, Dabbagh O, Chang SY, Park PK, Gong MN on behalf of USIITG-LIPS. Use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers and clinical outcomes among patients at-risk for acute lung injury. Presented at American Thoracic Society 2011 International Conference Vol 183 Meeting Abstracts
    PubMedGoogle Scholar
  • 92 Paola RD, Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury. PPAR Res 2007; 2007: 63745
    PubMedGoogle Scholar
  • 93 Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fundam Clin Pharmacol 2006; 20 (5) 429-447
    CrossrefPubMedGoogle Scholar
  • 94 Schaefer MB, Pose A, Ott J , et al. Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury. Eur Respir J 2008; 32 (5) 1344-1353
    CrossrefPubMedGoogle Scholar
  • 95 Liu D, Zeng BX, Zhang SH , et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med 2005; 33 (10) 2309-2316
    CrossrefPubMedGoogle Scholar
  • 96 Chen C, Xu S, Wang WX , et al. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res 2009; 40 (2) 79-88
    CrossrefPubMedGoogle Scholar
  • 97 Aoki Y, Maeno T, Aoyagi K , et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009; 77 (3) 311-319
    CrossrefPubMedGoogle Scholar
  • 98 Chima RS, Hake PW, Piraino G, Mangeshkar P, Denenberg A, Zingarelli B. Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. Crit Care Med 2008; 36 (10) 2849-2857
    CrossrefPubMedGoogle Scholar
  • 99 Moss M, Guidot DM, Steinberg KP , et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit Care Med 2000; 28 (7) 2187-2192
    PubMedGoogle Scholar
  • 100 Leitman IM. Curcumin for the prevention of acute lung injury in sepsis: is it more than the flavor of the month?. J Surg Res 2011; 20: 20
    PubMedGoogle Scholar
  • 101 Venkatesan N, Punithavathi D, Babu M. Protection from acute and chronic lung diseases by curcumin. Adv Exp Med Biol 2007; 595: 379-405
    PubMedGoogle Scholar
  • 102 Suresh MV, Wagner MC, Rosania GR , et al. Pulmonary administration of water-soluble curcumin complex reduces ALI severity. Am J Respir Cell Mol Biol 2012; 3: 3
    PubMedGoogle Scholar
  • 103 Bansal S, Chhibber S. Curcumin alone and in combination with augmentin protects against pulmonary inflammation and acute lung injury generated during Klebsiella pneumoniae B5055-induced lung infection in BALB/c mice. J Med Microbiol 2010; 59 (Pt 4) 429-437
    CrossrefPubMedGoogle Scholar
  • 104 Sun J, Yang D, Li S, Xu Z, Wang X, Bai C. Effects of curcumin or dexamethasone on lung ischaemia-reperfusion injury in rats. Eur Respir J 2009; 33 (2) 398-404
    PubMedGoogle Scholar
  • 105 Liu K, Shen L, Wang J , et al. The preventative role of curcumin on the lung inflammatory response induced by cardiopulmonary bypass in rats. J Surg Res 2010; 31: 31
    PubMedGoogle Scholar